Mind Medicine Inc (MNMD)
Official siteBIOTECHNOLOGY
Last updated: Jan 14, 2026 at 4:00 PM ET
Mind Medicine Inc (MNMD) Financials: Revenue, Profit and Cash Flow
Mind Medicine reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$108.68M, operating cash flow was -$79.13M and free cash flow was -$79.13M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$67.27M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $103.92M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | N/A | N/A | N/A | N/A | N/A |
| Dec 2018 | N/A | N/A | N/A | N/A | N/A |
| Dec 2017 | N/A | N/A | N/A | N/A | N/A |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
| Dec 2015 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $527.00K | $3.16M | $3.22M | $2.62M | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross profit | -$527.00K | -$3.16M | -$3.22M | -$2.62M | N/A | N/A | N/A | N/A | N/A | N/A |
| Research and development | $65.30M | $48.96M | $36.17M | $34.79M | $18.63M | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$103.92M | -$93.87M | -$66.33M | -$93.85M | -$33.03M | -$468.18K | -$861.94K | -$1.24M | -$111.25K | -$94.55K |
| Net income | -$108.68M | -$95.73M | -$56.80M | -$93.04M | -$34.10M | -$1.12M | -$857.94K | -$1.23M | -$179.90K | -$92.66K |
| EBITDA | N/A | -$92.57M | -$63.15M | -$91.24M | -$32.29M | N/A | -$851.26K | N/A | -$111.25K | -$92.66K |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4.84M | $0 | $0 | $0 | $0 |
| Gross profit | N/A | N/A | N/A | N/A | N/A | N/A | -$527.00K | $4.05M | -$800.00K | -$814.00K | -$805.00K | -$803.00K |
| Operating income | -$45.67M | -$40.90M | -$32.16M | -$32.46M | -$24.79M | -$24.46M | -$22.20M | -$22.20M | -$21.62M | -$29.18M | -$20.86M | -$13.90M |
| Net income | -$67.27M | -$42.74M | -$23.35M | -$34.74M | -$13.68M | -$5.85M | -$54.40M | -$23.86M | -$17.92M | -$29.13M | -$24.82M | -$4.90M |
Balance Sheet
As of Dec 2024, cash and equivalents exceeded long-term debt of $21.85M by $251.89M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $302.15M | $124.54M | $169.99M | $164.00M | $81.52M | $2.94M | $3.53M | $4.03M | $202.75K | $291.66K |
| Current assets | $281.62M | $103.87M | $146.06M | $137.22M | $81.52M | $2.94M | $198.63K | $1.77M | $136.19K | $186.40K |
| Cash and equivalents | $273.74M | $99.70M | $142.14M | $133.54M | $80.09M | $17.93K | $154.79K | N/A | $10.96K | N/A |
| Total liabilities | $60.70M | $46.41M | $19.08M | $12.34M | $5.65M | $198.96K | N/A | $80.44K | $75.47K | N/A |
| Short-term debt | N/A | N/A | $72.00K | N/A | N/A | N/A | N/A | $15.74K | N/A | N/A |
| Long-term debt | $21.85M | $14.13M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $241.45M | $78.13M | $150.92M | $151.66M | $75.87M | $2.74M | $3.52M | $3.95M | $127.28K | $284.17K |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $236.92M | $265.09M | $275.32M | $302.15M | $319.77M | $268.14M | $275.53M | $124.54M | $141.55M | $142.09M | $155.53M | $169.99M |
| Total liabilities | $106.32M | $79.69M | $52.52M | $60.70M | $57.58M | $66.10M | $79.47M | $46.41M | $45.57M | $36.11M | $25.18M | $19.08M |
| Cash and equivalents | $19.96M | $33.39M | $82.85M | $273.74M | $295.28M | $243.13M | $252.33M | $99.70M | $117.70M | $116.89M | $129.41M | $142.14M |
| Shareholder equity | $130.60M | $185.40M | $222.81M | $241.45M | $262.19M | $202.05M | $196.06M | $78.13M | $95.98M | $105.97M | $130.34M | $150.92M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$79.13M | -$64.36M | -$50.14M | -$45.82M | -$23.60M | -$208.12K | -$722.45K | -$665.98K | -$26.64K | -$46.56K |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $313.46K | $1.04M | $2.15M | $30.10K | $0 |
| Free cash flow | -$79.13M | -$64.36M | -$50.14M | -$45.82M | -$23.60M | -$521.58K | -$1.77M | -$2.82M | -$56.73K | -$46.56K |
| Investing cash flow | N/A | N/A | N/A | -$297.00K | -$297.00K | -$213.15K | $541.34K | -$3.67M | $32.83K | $41.86K |
| Financing cash flow | $253.20M | $21.85M | $59.05M | $98.82M | $96.70M | $288.36K | $312.05K | $4.35M | N/A | N/A |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.57M | -$29.60M | -$29.42M | -$25.35M | -$17.19M | -$19.99M | -$16.60M | -$20.56M | -$16.63M | -$13.85M | -$13.33M | -$12.85M |
| Free cash flow | -$29.57M | N/A | -$29.42M | -$25.35M | N/A | N/A | -$16.60M | -$20.56M | -$16.63M | -$13.85M | -$13.33M | -$12.85M |
Frequently Asked Questions About MNMD
What is Mind Medicine's annual revenue?
Mind Medicine reported revenue of $0 for the fiscal year ended Dec 31, 2024.
Is Mind Medicine profitable?
No. Mind Medicine reported net income of -$108.68M for the fiscal year ended Dec 31, 2024.
How much free cash flow does MNMD generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$79.13M minus capital expenditures of $0 produced free cash flow of -$79.13M.
How much debt does Mind Medicine have?
The balance sheet dated Dec 31, 2024 reported long-term debt of $21.85M and cash and equivalents of $273.74M.
MNMD pages: Overview, Financials